DAVID M. SALERNO, M.D., Ph.D.; MORRISON HODGES, M.D.; GREGORY GRANRUD, M.D.; PATRICIA SHARKEY, R.N.
In a randomized placebo-controlled double-blind trial, we compared flecainide to quinidine for treatment of ventricular ectopic depolarizations in 19 patients. The mean percent suppression of total ventricular ectopic depolarizations was 95% for flecainide and 56% for quinidine (p < 0.05). A greater than 80% reduction of total ventricular ectopic depolarizations was obtained in eight of nine patients given flecainide and in five of ten patients given quinidine (p = 0.09). After the randomized protocol, the patients who had received quinidine were given flecainide; 9 of the 10 patients had greater than 80% reduction of total ventricular ectopic depolarizations. Flecainide produced 100% suppression of nonsustained ventricular tachycardia and 99.5% suppression of paired ventricular depolarizations. Flecainide prolonged the PR and QRS intervals; quinidine prolonged the PR and JTC intervals. Side effects were commoner with quinidine than flecainide (p = 0.06). Three other patients failed to complete the protocol because of serious adverse experiences.
Learn more about subscription options.
Register Now for a free account.
SALERNO DM, HODGES M, GRANRUD G, SHARKEY P. Comparison of Flecainide with Quinidine for Suppression of Chronic Stable Ventricular Ectopic Depolarizations: A Double-Blind Randomized Study in Ambulatory Outpatients. Ann Intern Med. 1983;98:455–460. doi: 10.7326/0003-4819-98-4-455
Download citation file:
Published: Ann Intern Med. 1983;98(4):455-460.
Cardiology, Rhythm Disorders and Devices.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only